Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006483 · ClinicalTrials.gov registry record · Phase 2
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00006483 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 27 participants.
The verdict
NCT00006483, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung. PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who have kidney cancer that has spread to the lung.
Interventions
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2000-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006483
The ClinicalTrials.gov registry entry for NCT00006483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sargramostim is the first listed.
NCT00006483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006483 about?
NCT00006483 is a clinical study titled "Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung". RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung. PURPOSE: Phase II trial to study the effectiveness of sargramost...
What is the current status of trial NCT00006483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2000-10. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00006483?
The interventions under investigation include: sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006483?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.